People: argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

2:29am IST
Change (% chg)

$1.99 (+1.45%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rosenberg, Anthony 

Mr. Anthony A. (Tony) Rosenberg has served as Non-Executive Independent Director of argenx SE since April 26, 2017. He currently serves as CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing and mergers and acquisitions. Mr. Rosenberg has also been a Managing Director of MPM Capital, a venture capital firm, since April 2015. From January 2013 until February 2015, he served as Corporate Head of M&A and Licensing at Novartis Pharma. He served as Global Head of Business Development and Licensing at Novartis Pharma from March 2005 to December 2012. Mr. A. A. Rosenberg holds non-executive board memberships Radius Health Inc., TriNetX, Inc., iOmx Therapeutics AG, Cullinan Oncology Inc. and Oculis SA. Mr. A. A. Rosenberg has a B.Sc. (Hons) from the University of Leicester and a M.Sc. Physiology from the University of London. He is Member of the Audit Committee of the Company.

Basic Compensation

Total Annual Compensation, EUR 487,400
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 487,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --